Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labiana HealthFRA:8RK -0.76%57 Operating Margin % is 5.74% as of Dec. 2025, which is 109% above its 10-year median of 2.75. GuruFocus rates FRA:8RK with a GF Score™ of 57/100 and a GF Value™ of €3.54 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 961 Drug Manufacturers companies, Labiana Health ranks better than 54.63% on this metric.
Labiana Health SA has recorded a loss in operating income at least once over the past 3 years.
Labiana Health (FRA:8RK) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Labiana Health Operating Margin % Related Terms
Labiana Health Operating Margin % Historical Data
* Premium members only.
The historical data trend for Labiana Health's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8RK vs ZTS, UTHR, VTRS: Operating Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labiana Health Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labiana Health's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Labiana Health's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Labiana Health's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labiana Health (FRA:8RK) has a Operating Margin % of 5.74% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Labiana Health and its competitors. This is 109% above median its historical median of 2.75. According to the industry distribution chart, Labiana Health ranks #436 out of 961 companies in the Drug Manufacturers industry, placing it in the top 45.4%.
Is Labiana Health's Operating Margin % too high?
Labiana Health's current Operating Margin % of 5.74% is 109% above median its 10-year median of 2.75. The Drug Manufacturers industry median Operating Margin % is 7.57. Labiana Health's value of 5.74% is 24.2% below this industry median. Based on the distribution chart, Labiana Health ranks #436 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Labiana Health has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labiana Health's Operating Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labiana Health ranks #436 out of 961 companies for Operating Margin %. This puts Labiana Health in the upper half of its industry. The industry median Operating Margin % is 7.57. Labiana Health's value of 5.74% is 24.2% below this benchmark. While the company's 10-year median is 2.75 vs. the industry median of 7.57, Labiana Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.57, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labiana Health's current Operating Margin % of 5.74% is 24.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Labiana Health and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labiana Health's current Operating Margin % is 5.74%, which is 109% above median its own 10-year median of 2.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labiana Health stock overvalued right now?
Based on GuruFocus' analysis, Labiana Health (FRA:8RK) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.54, compared to a current price of €6.55 — trading 85% above its estimated fair value. The current Operating Margin % is 5.74%, which is 109% above median its 10-year median of 2.75 and 24.2% below the Drug Manufacturers industry median of 7.57. Labiana Health's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Labiana Health (FRA:8RK), the current Operating Margin % is 5.74% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labiana Health (FRA:8RK) Overvalued in 2026?
Based on GuruFocus' analysis, Labiana Health stock appears to be overvalued.
The current stock price of €6.55 is trading 85% above its estimated GF Value™ of €3.54.
GuruFocus considers Labiana Health to be Significantly Overvalued.
Key valuation signals for FRA:8RK:
Operating Margin %: 5.74% (109% above median its 10-year median of 2.75)
GF Value™: €3.54 vs. price of €6.55 (85% above fair value)
Industry Position: 24.2% below the Drug Manufacturers median (#436 of 961)
No single metric tells the full story. See the FRA:8RK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include a GMP manufacturer for EU animal and human health industries, a manufacturer specializing in sterile and lyophilized dosage forms, and a source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol. The company operates in two segment Animal Health and Human Health.
57GF Score
Get the complete analysis for FRA:8RK
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8RK has been successfully added to your 
